建立阿片戒断研究与评估的研究议程
本文指出阿片危机是国际公共卫生问题,阿片使用障碍治疗主要围绕戒断管理;过去50年抗抑郁药研发超90种而阿片使用障碍药物仅5种,认为投资不足部分源于对戒断综合征理解不足。文章总结戒断定义无共识、18个量表可测10-550种症状等重大差距,并提出九项可操作研究目标。
要点
- 阿片戒断定义缺乏共识,18个量表可测量10-550种症状,影响严重度评估准确性。
- 过去50年抗抑郁药研发超90种,阿片使用障碍药物仅5种,投资不足与戒断理解不足相关。
- 提出九项研究目标,涵盖共识定义、芬太尼等不同阿片暴露后症状学、 precipitated withdrawal、共暴露影响等。
核心结论
- 对阿片戒断综合征理解不足可能部分导致治疗研发投资不足,需建立国际研究议程以推动戒断管理和阿片使用障碍治疗的变革性进展。
研究设计与样本
- 本文为Personal View(个人观点)文章,总结阿片戒断理解中的重大差距并提出九项可操作研究目标。
主要发现
- 过去50年开发了90多种抗抑郁药,而阿片使用障碍药物仅5种。
- 领域内对戒断应如何精确定义无共识,18个量表可测量10-550种戒断症状。
- 对戒断理解不精确可能导致高估或低估个体戒断综合征严重度或不同候选药物的潜在疗效。
关键数值与推荐
- 九项可操作目标包括:制定阿片戒断共识定义;理解不同阿片(尤其芬太尼)暴露后戒断症状学;理解 precipitated opioid withdrawal;理解其他药物(如 xylazine 和兴奋剂)共暴露如何影响戒断表达;检查戒断表型个体差异;精确描述迁延性戒断综合征;识别戒断严重度生物标志物;识别戒断严重度预测因子;理解哪些症状与治疗脱落或复发最密切相关。
- 美国食品药品监督管理局(FDA)近期建立了阿片戒断的正式适应症,激发了戒断管理药物开发兴趣。
临床怎么用
- 临床应关注阿片戒断定义不统一和评估工具差异对严重度判断及疗效评估的影响。
- 可参考九项研究目标方向,关注不同阿片暴露、共暴露药物及个体差异对戒断表现的影响。
- FDA建立阿片戒断正式适应症后,需推动研究以帮助产业识别新类别药物。
局限性
- 本文为Personal View观点文章,未报告原始研究数据、样本量或系统检索方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The opioid crisis is an international public health concern. Treatments for opioid use disorder centre largely on the management of opioid withdrawal, an aversive collection of signs and symptoms that contribute to opioid use disorder. Whereas in the past 50 years more than 90 medications have been developed for depression, only five medications have been developed for opioid use disorder during this period. We posit that underinvestment has occurred in part due to an underdeveloped understanding of opioid withdrawal syndrome. This Personal View summarises substantial gaps in our understanding of opioid withdrawal that are likely to continue to limit major advancements in its treatment. There is no firm consensus in the field as to how withdrawal should be precisely defined; 10-550 symptoms of withdrawal can be measured on 18 scales. The imprecise understanding of withdrawal is likely to result in overestimating or underestimating the severity of an individual's withdrawal syndrome or potential therapeutic effects of different candidate medications. The severity of the opioid crisis is not remitting, and an international research agenda for the study and assessment of opioid withdrawal is necessary to support transformational changes in withdrawal management and treatment of opioid use disorder. Nine actionable targets are delineated here: develop a consensus definition of opioid withdrawal; understand withdrawal symptomatology after exposure to different opioids (particularly fentanyl); understand precipitated opioid withdrawal; understand how co-exposure of other drugs (eg, xylazine and stimulants) influences withdrawal expression; examine individual variation in withdrawal phenotypes; precisely characterise the protracted withdrawal syndrome; identify biomarkers of opioid withdrawal severity; identify predictors of opioid withdrawal severity; and understand which symptoms are most closely associated with treatment attrition or relapse. The US Food and Drug Administration recently established a formal indication for opioid withdrawal that has invigorated interest in drug development for opioid withdrawal management. Action is now needed to support these interests and help industry identify new classes of medications so that real change can be achieved for people with opioid use disorder.
引用
- Dunn KE, Strain EC. Establishing a research agenda for the study and assessment of opioid withdrawal. Lancet Psychiatry. 2024. PMID: 38521089. doi:10.1016/S2215-0366(24)00068-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。